Clinical trials: Bladder Cancer Recurrence
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
This phase Ib trial evaluates the best dose, potential benefits, and/or side effects of erdafitinib in combination with enfortumab vedotin in treating patients with bladder cancer that has spread from where it first started…
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma
- Trial name
- NCT04963153
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 9 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Green tea extract (Polyphenon® E) contains certain ingredients that may slow the growth of tumor cells and prevent the…
- Trial name
- NCT00088946
- Testing
- Polyphenon E, erlotinib hydrochloride
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Bladder Cancer
BCG With or Without Mitomycin in Treating Patients With Bladder Cancer
RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop tumor cells from growing.
- Trial name
- NCT00023842
- Testing
- BCG vaccine, mitomycin C, adjuvant therapy
- Where
- 16 sites in Belgium, Italy and 4 more
- Volunteers
- 97 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Superficial Bladder Cancer
Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer
The aim of this phase Ib/IIa study is to investigate the maximum tolerable concentration of abnobaVISCUM® Fraxini for intravesical instillation in patients with superficial bladder cancer.
- Trial name
- NCT02007005
- Testing
- abnobaVISCUM Fraxini
- Where
- 2 sites in Egypt, Germany
- Volunteers
- 37 people
- Sponsor
- Abnoba Gmbh
Bladder Cancer
Study of the Efficacy of Maintenance Therapy Using Uracil-tegafur (UFT) or Bacille Calmette-Guerin (BCG) for the Prevention of Recurrences of Superficial Bladder Cancer (EMBARK Study)
The purpose of this prospective randomized controlled study is to prove the non-inferiority of UFT maintenance therapy to BCG maintenance therapy for preventing recurrences of superficial bladder cancer.
- Trial name
- NCT01082510
- Testing
- Bacille Calmette-Guerin, uracil-tegafur
- Where
- Japan
- Volunteers
- 288 people
- Sponsor
- Urological Oncology Council of Northern Tokyo
Upper Tract Urothelial Carcinoma, Bladder Recurrence
Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas
The purpose of this study is to evaluate the efficacy of prophylactic intravesical chemotherapy (different chemotherapy drugs and dosage regimen) in the prevention of bladder recurrence after nephroureterectomy for upper tract…
- Trial name
- NCT02547350
- Testing
- pharmorubicin or pirarubicin
- Volunteers
- 200 people
- Sponsor
- Xuesong Li
Non-Muscle Invasive Bladder Cancer, Self Efficacy
The Effect of Telephone-Assisted Smoking Cessation Program in Patients Diagnosed With Non-Muscle Invasive Bladder Cancer
This study will be carried out to examine the effect of telephone-assisted smoking cessation program on self-efficacy, smoking behavior, tumor recurrence and progression in patients with non-muscle invasive bladder cancer.
- Conditions
- Non-Muscle Invasive Bladder Cancer, Self Efficacy, Smoking Behaviors, Tumor Recurrence
- Trial name
- NCT05704231
- Testing
- Behavioral: Motivational Interviewing with WhatsApp video call
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bladder Carcinoma
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer
This phase I trial studies the side effects and best dose of pembrolizumab when given together with docetaxel or gemcitabine hydrochloride in treating patients with previously treated urothelial cancer that has spread to other…
- Conditions
- Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bladder Carcinoma, Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter, Regional Urothelial Carcinoma of the Renal Pelvis and Ureter
- Trial name
- NCT02437370
- Testing
- Pembrolizumab, Docetaxel, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of California, Davis
Bladder Cancer
Development of Multiphasic CT-based Delta-Radiomics Model for Predicting Postoperative Recurrence Risk in Bladder Cancer
This retrospective study included 316 bladder cancer patients
- Trial name
- NCT07251946
- Where
- China
- Volunteers
- 316 people
- Sponsor
- Lian Yang
Bladder Cancer, Breast Cancer
Docetaxel in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to compare the effectiveness of docetaxel in treating Caucasian and African American…
- Conditions
- Bladder Cancer, Breast Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00003565
- Testing
- docetaxel
- Where
- 74 sites in United States, Canada and 1 more
- Volunteers
- 109 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Bladder (Urothelial, Transitional Cell) Cancer, Nonmuscle Invasive Bladder Cancer
Implications of Post-Operative Irrigation Fluid's Osmolarity on the Recurrence of Non-Muscle Invasive Bladder Cancer Following Transurethral Resection
This randomized controlled trial will evaluate the efficacy of three bladder irrigation solutions - distilled water (DW), normal saline (NS), and hypertonic saline (HS) - as continuous bladder irrigation (CBI) following…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Nonmuscle Invasive Bladder Cancer, Irrigation, Hypertonic Saline
- Trial name
- NCT07279792
- Testing
- Continuous Bladder Irrigation with distilled water, Continuous Bladder Irrigation with normal saline, Continuous Bladder Irrigation with hypertonic saline
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Ain Shams University
Bladder Cancer, Kidney Cancer
Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants
RATIONALE: Studying samples of blood and urine from patients with cancer and from healthy participants in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Conditions
- Bladder Cancer, Kidney Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00900276
- Testing
- immunologic technique, laboratory biomarker analysis, mass spectrometry
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Bladder Cancer
Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells.
- Trial name
- NCT00014287
- Testing
- gemcitabine hydrochloride
- Sponsor
- University of Pittsburgh
Bladder Cancer
Can We Predict of the Response of High Risk Non Muscle Invasive Bladder Cancer Patients to Intravesical Bacillus Calmette-Guerin? The Role of Immunological Markers
Intravesical BCG is the mainstay adjuvant management of high risk NMIBC. Adequacy of immune system stimulation is the determinant factor for patient response to BCG.
- Trial name
- NCT04723121
- Testing
- Urine ELISA for immunological markers (IL-2 and IL-10), Reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) analysis
- Where
- Egypt
- Volunteers
- 204 people
- Sponsor
- Mansoura University
Bladder Cancer, Breast Cancer
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
RATIONALE: OGX-011 may kill tumor cells by blocking some of the proteins that may cause tumor cells to grow. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Conditions
- Bladder Cancer, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00471432
- Testing
- custirsen sodium, docetaxel, pharmacological study
- Volunteers
- 40 people
- Sponsor
- NCIC Clinical Trials Group
Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
This study evaluates the efficacy, as measured by the objective response rate, of STI-3031, an anti-PD-L1 antibody, in previously treated patients with selected advanced lymphomas or biliary tract cancer.
- Conditions
- Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma, Biliary Tract Cancer, Extranodal NK T Cell Lymphoma, Nasal
- Trial name
- NCT03999658
- Testing
- STI-3031
- Sponsor
- Sorrento Therapeutics, Inc.
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center